Plain English Summary
Background and study aims
Acne is a common skin condition which causes spots to develop on the skin, usually the face, chest and back. Even cases of mild acne can be distressing, as not only can it make people feel self-conscious, it can be painful. The majority of treatments for acne involve applying medications directly to the skin (topical medication), such as creams, gels and lotions. These products can contain a wide range of different chemicals, including retinoids (vitamin A by-products that help to remove dead skin cells from the surface of skin), antibiotics (which kill bacteria on the skin that can cause infections leading to spots) and keratolytic substances (peeling agents). When acne affects the chest or back, it can be difficult to apply topical medications in the form of creams, gels and lotions as these areas can be hard to reach. Sprays are therefore considered to be a far more convenient treatment option, as they are able to reach where the sufferer otherwise would not be able to. The aim of this study is to compare three different acne spray formulations, in order to find out if a spray containing retanoids, antibiotics and keratolytic substances is more effective than sprays containing keratolytic substances alone.
Who can participate?
Adults with mild to moderate acne on the back and chest.
What does the study involve?
Participants are randomly allocated to receive one of three products. The first product is a new spray which contains retinol and hydroxypinacolone retinoate (vitamin A by-products), an antibacterial product, salicylic acid (a plant hormone commonly used to treat common skin and foot warts) and, vitamin E. The second and third products both contain different keratolytic substances (peeling agents that help to soften and shed the outer layer of skin). All products are applied twice a day for six weeks using four to five sprays on the affected area of skin. At the start of the study and after six weeks, participants in all groups have their acne examined to find out if there has been any improvement. Participant are also interviewed after six weeks in order to find out how their skin has reacted to the spray that they used.
What are the possible benefits and risks of participating?
Participants may benefit from an improvement to their acne as a result of using the treatment sprays. There are no notable risks involved with taking part in the study, although there is a chance than the product used may not be effective or cause skin irritation.
Where is the study run from?
Clinica di Dermatologia Seconda Università Napoli (Italy)
When is the study starting and how long is it expected to run for?
December 2014 to February 2016
Who is funding the study?
Difa Cooper (Italy)
Who is the main contact?
Dr Massimo Milani
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
BR2015/1
Study information
Scientific title
Efficacy and local tolerability of different spray products in the treatment of mild to moderate acne of the back and chest: A controlled, three-arm, assessor-blinded prospective trial
Acronym
Study hypothesis
The aim of this study is to evaluate whether a spray containing retinoids, antibacterial, emollient and keratolytic substances is more effective than other two products containing containing keratolytic and emollient compounds only at treating moderate acne of the chest and back.
Ethics approval
Policlinico Federico II Naples, 10/01/2015
Study design
Prospective observer-masked three arm randomised parallel trial
Primary study design
Interventional
Secondary study design
Randomised parallel trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
No specific participant information sheet available, please use the contact details below to request a further information.
Condition
Truncal acne vulgaris
Intervention
Participants are randomly allocated in a 1:1:1 ratio to receive one of three products.
Product 1: A new spray formulation containing 0.15% of two vitamin A derivatives (retinol and hydroxypinacolone retinoate) carried in a patented glycospheres system (RetinSphere®), an antimicrobial peptide (BIOPEP.15), salicylic acid and, vitamin E (BR).
Product 2: A spray formulation containing triethyl citrate and ethyl linoleate, GT-peptide-10, salycilic acid 0,5% and Zinc Lattate.
Product 3: A spray formulation containing betaine, glycine and salicylic acid 2% (SP).
All products are to be applied twice daily (one application in the morning and one application in the evening) for 6 consecutive weeks. The total amount of product is 4/5 puffs per application (a total of 1.2/1.5 ml), in order to cover chest and back areas.
All participants are followed up at six weeks.
Intervention type
Drug
Phase
Phase III/IV
Drug names
1. Bioretix ultra spray
2. Aknicare CB
3. Salipil spray
Primary outcome measure
Clinical evolution of acne lesions is measured using the Global Acne Grading System (GAGS) at baseline and 6 weeks.
Secondary outcome measures
Skin tolerability is measured by evaluating skin irritation (erythema and burning) and skin xerosis using a quantitative score from 0(no symptom) to 3(relevant symptom) at 6 weeks.
Overall trial start date
01/12/2014
Overall trial end date
01/02/2016
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Aged 18 years and over
2. Presence of mild to moderate acne involving back and chest regions (truncal acne)
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
75 (a total of 25 subjects per treatments arm)
Participant exclusion criteria
1. Severe forms of acne requiring systemic treatments
2. Other severe skin conditions
3. Use of topical acne medications such as tretinoin, benzoyl peroxide or topical antibiotics within 2 weeks
4. Use of oral antibiotics within 30 days
5. Use of systemic corticosteroids within 4 weeks
6. Body Mass Index >30
Recruitment start date
02/02/2015
Recruitment end date
01/12/2016
Locations
Countries of recruitment
Italy
Trial participating centre
Clinica di Dermatologia Seconda Università Napoli
Via Pansini
Naples
0182
Italy
Funders
Funder type
Industry
Funder name
Difa Cooper
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Planned publication in a peer reviewed journal.
Intention to publish date
30/09/2016
Participant level data
Stored in repository
Basic results (scientific)
Publication list